B+
Bull case
25%
Probability
Target price
$4.25
+181.5% vs current
CRDF
Cardiff OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.85
+22.5% vs current
B-
Bear case
25%
Probability
Target price
$0.65
-57.0% vs current
AI sentiment snapshot
Latest data as of 2026-06-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+91.9
Score
AI commentary
Primary-source news flow is real and clinically constructive, but this is still a low-coverage, event-driven small-cap biotech with financing, legal, and peer-comparability limitations. No reliable analyst-revision set or social-sentiment signal was provided, so confidence should stay moderate rather than aggressive. The near-term question is whether ASCO and the mid-2026 Phase 3 disclosure extend the re-rate without bringing CRDF-005 financing or the Nerviano dispute back to the front of the tape.
RankAlpha Sentiment Codex - 2026-06-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-02eventASCO update on CRDF-004 dataHigh impact
Cardiff said it will present updated randomized Phase 2 CRDF-004 data at ASCO, building on the earlier signal of 72.2% confirmed ORR and PFS HR 0.37 versus combined standard of care; a clean update would reinforce the clinical re-rate, while a softer readout would likely compress expectations [#SEC-8K-2026-05-14].
2026-06-30catalystNerviano license dispute over onvansertib rightsHigh impact
Nerviano said it was terminating the license agreement and alleged breach tied to inventorship and development-effort claims, while Cardiff said the notice is ineffective and that it will continue to perform; this is a real legal overhang until resolved [#8-K-2026-05-29].
2026-07-31eventMid-2026 Phase 3 design disclosureHigh impact
Management said it completed an End-of-Phase 2 meeting with the FDA, selected the 30 mg dose with FOLFIRI/bev for the Phase 3 path, and plans to share additional trial and regulatory details in mid-2026; that disclosure is the next major de-risking milestone [#SEC-8K-2026-05-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology